Dr Reddys Laboratories Stock EBITDA
| RDY Stock | USD 13.60 0.39 2.79% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | 101.7 B | 106.8 B |
RDY | EBITDA |
Dr Reddys Laboratories Company EBITDA Analysis
Dr Reddys' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current Dr Reddys EBITDA | 88.42 B |
Most of Dr Reddys' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RDY EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as EBITDA. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Click cells to compare fundamentals
RDY EBITDA Historical Pattern
Today, most investors in Dr Reddys Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Dr Reddys' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's ebitda growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Dr Reddys ebitda as a starting point in their analysis.
Dr Reddys EBITDA |
| Timeline |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
RDY Ebitda
Ebitda |
|
According to the company disclosure, Dr Reddys Laboratories reported earnings before interest,tax, depreciation and amortization of 88.42 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The ebitda for all United States stocks is significantly lower than that of the firm.
RDY EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dr Reddys' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics of similar companies.Dr Reddys is currently under evaluation in ebitda category among its peers.
Dr Reddys ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dr Reddys' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dr Reddys' managers, analysts, and investors.Environmental | Governance | Social |
Dr Reddys Institutional Holders
Institutional Holdings refers to the ownership stake in Dr Reddys that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Dr Reddys' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Dr Reddys' value.| Shares | Bank Of America Corp | 2024-09-30 | 858.8 K | Goldman Sachs Group Inc | 2024-09-30 | 556 K | Allspring Global Investments Holdings, Llc | 2024-12-31 | 534.3 K | Allianz Asset Management Ag | 2024-12-31 | 475.4 K | Gqg Partners Llc | 2024-09-30 | 437 K | Rhumbline Advisers | 2024-12-31 | 430.1 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 409.4 K | Healthcare Of Ontario Pension Plan Trust Fund | 2024-09-30 | 343.8 K | Man Group Plc | 2024-09-30 | 208.5 K | Robeco Institutional Asset Management Bv | 2024-12-31 | 11.4 M | Fisher Asset Management, Llc | 2024-12-31 | 2.5 M |
RDY Fundamentals
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.1 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 11.39 B | ||||
| Shares Outstanding | 833.12 M | ||||
| Shares Owned By Insiders | 0.03 % | ||||
| Shares Owned By Institutions | 14.96 % | ||||
| Number Of Shares Shorted | 15.9 M | ||||
| Price To Earning | 31.58 X | ||||
| Price To Book | 3.10 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 279.16 B | ||||
| Gross Profit | 184.65 B | ||||
| EBITDA | 88.42 B | ||||
| Net Income | 55.68 B | ||||
| Cash And Equivalents | 2.93 B | ||||
| Cash Per Share | 208.58 X | ||||
| Total Debt | 20.02 B | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 1.98 X | ||||
| Book Value Per Share | 381.36 X | ||||
| Cash Flow From Operations | 45.43 B | ||||
| Short Ratio | 7.51 X | ||||
| Earnings Per Share | 0.74 X | ||||
| Price To Earnings To Growth | 4.51 X | ||||
| Target Price | 15.58 | ||||
| Number Of Employees | 27.05 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 11.49 B | ||||
| Total Asset | 387.52 B | ||||
| Retained Earnings | 265.26 B | ||||
| Working Capital | 152.01 B | ||||
| Current Asset | 1.81 B | ||||
| Current Liabilities | 976 M | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 0.72 % | ||||
| Net Asset | 387.52 B | ||||
| Last Dividend Paid | 8.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.